Reply
- PMID: 26696314
- DOI: 10.1097/IAE.0000000000000918
Reply
Comment on
-
Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab.Retina. 2014 Dec;34(12):2439-43. doi: 10.1097/IAE.0000000000000238. Retina. 2014. PMID: 24999721
-
Correspondence.Retina. 2016 Feb;36(2):e9-e10. doi: 10.1097/IAE.0000000000000917. Retina. 2016. PMID: 26655619 No abstract available.
Similar articles
-
Reply: To PMID 24999721.Retina. 2015 Aug;35(8):e54-5. doi: 10.1097/IAE.0000000000000682. Retina. 2015. PMID: 26166802 No abstract available.
-
Correspondence.Retina. 2016 Feb;36(2):e9-e10. doi: 10.1097/IAE.0000000000000917. Retina. 2016. PMID: 26655619 No abstract available.
-
Correspondence.Retina. 2015 Aug;35(8):e54. doi: 10.1097/IAE.0000000000000681. Retina. 2015. PMID: 26166801 No abstract available.
-
Use of Anti-VEGF Drugs in Retinal Vein Occlusions.Curr Drug Targets. 2020;21(12):1181-1193. doi: 10.2174/1389450121666200428101343. Curr Drug Targets. 2020. PMID: 32342813 Review.
-
Clinical Trials in Branch Retinal Vein Occlusion.Middle East Afr J Ophthalmol. 2016 Jan-Mar;23(1):38-43. doi: 10.4103/0974-9233.172294. Middle East Afr J Ophthalmol. 2016. PMID: 26957837 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources